Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methadone + ketamine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of methadone, a synthetic opioid that acts primarily as a full μ-opioid receptor agonist, but uniquely also functions as an NMDA receptor antagonist[3][7] and inhibits serotonin and norepinephrine uptake[3], and ketamine, a noncompetitive NMDA receptor antagonist[1]. This combination has been studied for management of post-surgical pain, neuropathic pain, and as part of fast-track cardiac anesthesia protocols.
- Other names
- ketamine and methadonemethadone plus ketamineketamine/methadone combination
02
Targets
SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on methadone + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methadone + ketamine.